Quality of work life and Generation Y: How gender and organizational type moderate job satisfaction

Purpose: The purpose of this paper is to examine how Quality of Work Life (QWL) influences job satisfaction and to test if gender and organizational type moderate this relationship for Gen-Y. Design/methodology/approach: Questionnaire data were collected from 328 Gen-Y employees in European hospitality businesses. Drawing on generational theory, social role theory, and Person-Environment (P-E) fit theory, we discuss how gender and organizational types (i.e., independent vs. corporate structures) moderate Gen-Y’s QWL-job satisfaction relationship. Findings: 1.) Gender and organizational type influence the QWL-job satisfaction relationship for Gen-Y. 2.) Job security does not change job satisfaction levels for female employees while high levels of job security negatively influence job satisfaction for male employees. 3.) Receiving appreciation at work increases job satisfaction for both women and men but, when receiving little appreciation at work, women remain more satisfied. 4.) Having opportunities to contribute to decisions positively affects Gen-Y’s job satisfaction. 5.) Having the right to say is more important in independent organizations, while the opportunity to realize an employee’s own potential leads to higher job satisfaction in corporate organizations. Originality/value: The study contributes to the limited empirical scholarly research, adding to a deeper understanding of influencing factors of Gen-Y’s QWL-job satisfaction relationship

3D finite element model of aqueous outflow to predict the effect of femtosecond laser created partial thickness drainage channels

Background and Objectives Partial thickness drainage channels can be created with femtosecond lasers in the translucent sclera for the potential treatment of glaucoma. We present a 3D finite element model (FEM) that can predict the effect of these channels on aqueous humor (AH) outflow and intraocular pressure (IOP). Study Design/Materials and Methods A 3D model was developed based on a 2D model for the intact eye using COMSOL (Comsol, Inc., MA) finite element software. Different values of permeability were entered into the 3D model for the AH pathway and for the partial thickness channel. To obtain experimental data for model validation, one partial thickness channel was created in each of three enucleated rabbit eyes with a femtosecond laser tuned to 1.7 µm wavelength. Aqueous outflow rates were measured with the perfusion method before and after the laser treatments at different levels of IOP and then compared to IOP values predicted by the model. Results The experiments indicated that the rate of the AH outflow was increased in each of three eyes after the laser treatment. Assuming a constant rate of AH production the 3D model predicted IOP reductions ranging from 67.2% to 80.6% as the effect of the laser created channels. These predictions were in reasonable agreement with experimentally adjusted IOP values during the perfusion measurements. Conclusions The developed 3D FEM has the potential to predict IOP reduction caused by partial thickness drainage channels created with the femtosecond laser in the sclera. Such a model may also be used to determine optimal channel dimensions for a specified increase in outflow facility and reduction in IOP. Laser Surg. Med. 40:188–195, 2008. © 2008 Wiley-Liss, Inc.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/58067/1/20608_ftp.pd

Fluid dynamics of a novel micro-fistula implant for the surgical treatment of glaucoma,”

PURPOSE. The purpose of this study was to describe the fluidics of a novel non-valved glaucoma implant designed to prevent hypotony and compare the fluidics of this device with two commonly used non-valved glaucoma devices. METHODS. The XEN 45 micro-fistula implant was designed to limit hypotony by virtue of its length and width according to the Hagen-Poiseuille equation. Flow testing was performed using a syringe pump and pressure transducer at multiple flow rates. The pressure differentials across the XEN implant, the Ex-Press implant, and 10 mm of silicone tubing from a Baerveldt implant at a physiologic flow rate (2.5 lL/min) were extrapolated. RESULTS. The XEN 45 achieved a steady-state pressure calculated at 7.56 mm Hg at 2.5 lL/min. At the same flow rate, the Ex-Press device and Baerveldt tubing reached steady-state pressures of 0.09 and 0.01 mm Hg, respectively. CONCLUSIONS. Under flow testing, the XEN micro-fistula implant was able to maintain backpressure above numerical hypotony levels without the use of complex valve systems. This is due to the XEN implant's design, derived from the principles that dictate Newtonian fluids

Hsa-miR-375 is a predictor of local control in early stage breast cancer

Background: A long-term analysis by the Early Breast Cancer Trialist Group (EBCTG) revealed a strong correlation between local control and cancer-specific mortality. MicroRNAs (miRs), short (20-25 nucleotides) non-coding RNAs, have been described as prognosticators and predictors for breast cancer in recent years. The aim of the current study was to identify miRs that can predict local control after breast conserving therapy (BCT) in early stage breast cancer. Results: Clinical data of 46 early stage breast cancer patients with local relapse after BCT were selected from the institutional database. These patients were matched to 101 control patients showing identical clinical features but without local relapse. The study was conducted in two steps. (1) In the pilot study, 32 patients (16 relapses versus 16 controls) were screened for the most de-regulated microRNAs (= candidate microRNAs) in a panel of 1250 miRs by microarray technology. Eight miRs were found to be significantly de-regulated. (2) In the validation study, the candidate microRNAs were analyzed in an independent cohort of 115 patients (30 relapses versus 85 controls) with reverse transcription quantitative polymerase chain reaction (RT-qPCR). From these eight candidates, hsa-miR-375 could be validated. Its median fold change was 2.28 (Mann-Whitney U test, corrected p value = 0.008). In the log-rank analysis, high expression levels of hsa-miR-375 correlated with a significantly higher risk of local relapse (p = 0.003). In a multivariate analysis (forward stepwise regression) including established predictors and prognosticators, hsa-miR-375 was the only variable that was able to distinguish the statistical significance between relapse and control groups (raw p value = 0.000195 HR = 0.76, 95 % CI 0.66-0.88;corrected p value = 0.005). Conclusions: Hsa-miR-375 predicts local control in patient with early stage breast cancer, especially in estrogen receptor alpha (ER-alpha)-positive patients. It can therefore serve as an additional molecular marker for treatment choice independently from known predictors and prognosticators. Validation in larger prospective studies is warranted

Physiology and Pharmacology Episcleral Venous Pressure and IOP Responses to Central Electrical Stimulation in the Rat

PURPOSE. Histological evidence suggests a role for the central nervous system in controlling episcleral venous pressure (EVP). Based on prior studies that identified candidate regions in the brain stem, the present study assessed the effect of electrical stimulation at the location of the superior salivatory nucleus (SSN) on EVP in rats. METHODS. Male Sprague-Dawley rats (n ¼ 11) were anesthetized using pentobarbital sodium (50 mg/kg intraperitoneally initially, supplemented intravenously [IV] as needed) and paralyzed with gallamine triethiodide (1 mg/kg, IV). The animals were artificially ventilated and the femoral artery and vein were cannulated for blood pressure measurement and drug administration. Carotid blood flow was measured with an ultrasound flow probe and heart rate with a cardiotachometer. IOP was measured through a cannula in the vitreous compartment and EVP was measured through a micropipette in episcleral veins using the servonull technique. After a craniotomy was performed, a unipolar stainless steel electrode was inserted into the brainstem at the coordinates of the SSN using a stereotactic instrument. Stimulations were performed at 20Hz, 9 lA, 1 ms pulse duration, and 200 pulses. RESULTS. Stimulation at the SSN coordinates increased IOP from 10.6 6 0.4 to 11.8 6 0.6 mm Hg (P < 0.01) and EVP from 7.8 6 1.3 to 10.7 6 1.1 mm Hg (P < 0.01). Mean arterial pressure, carotid blood flow, and heart rate remained unaltered. CONCLUSIONS. The present study indicates that the SSN may participate in regulating EVP. Keywords: episcleral venous pressure, superior salivatory nucleus, stimulation, IOP S teady-state IOP can be described by the Goldmann equation as the relationship between aqueous flow, uveoscleral outflow, outflow facility, and episcleral venous pressure (EVP). 1,2 EVP is the pressure that has to be overcome for fluid to leave the eye via the trabecular outflow pathway and, in humans under normal conditions, EVP accounts for roughly 60% of IOP. Despite its importance for IOP homeostasis, the physiology of the episcleral venous pressure is poorly understood. The current de facto standard for measuring EVP is the venomanometer described by Zeimer et al. 12 Recently, a study by Samuels et al. The brainstem, however, appears to be the first relay station for nerves supplying the eye, and, thus, the nuclei there are likely to be more specialized than higher-order centers in the diencephalon. METHODS The study was approved by the institutional animal care and use committee of the University of Texas Health Science Center at San Antonio and conducted in accordance with the ARVO guidelines for animal use in vision research. All animals were euthanized with an anesthetic overdose at the end of the experiment without regaining consciousness. Animal Preparation Male Sprague Dawley rats (n ¼ 11, 305.4 6 8.6 g) were anesthetized using pentobarbital sodium (Sigma-Aldrich, 50 mg/kg intraperitoneally, supplemented intravenously as needed). A tracheotomy was performed and the animal was respire

High Molecular Weight Hyaluronan Promotes Corneal Nerve Growth in Severe Dry Eyes

The purpose of this study was to investigate the effect of high molecular weight hyaluronan (HMWHA) eye drops on subbasal corneal nerves in patients suffering from severe dry eye disease (DED) and to evaluate the damage of subbasal corneal nerves associated with severe DED. Designed as an international, multicenter study, 16 patients with symptoms of at least an Ocular Surface Disease Index (OSDI) score of 33, and corneal fluorescein staining (CFS) of at least Oxford grade 3, were included and randomized into two study arms. The control group continued to use their individual optimum artificial tears over the study period of eight weeks; in the verum group, the artificial tears were substituted by eye drops containing 0.15% HMWHA. At the baseline visit, and after eight weeks, the subbasal nerve plexus of 16 patients were assessed by confocal laser scanning microscopy (CSLM). The images were submitted to a masked reading center for evaluation. Results showed a significant increase of total nerve fiber lengths (CNFL) in the HMWHA group (p = 0.030) when compared to the control group, where the total subbasal CNFL did not significantly change from baseline to week 8. We concluded that in severe DED patients, HMWHA from topically applied eye drops could cross the epithelial barrier and reach the subbasal nerve plexus, where it exercised a trophic effect

The HYLAN M Study: Efficacy of 0.15% High Molecular Weight Hyaluronan Fluid in the Treatment of Severe Dry Eye Disease in a Multicenter Randomized Trial

The aim of the HYLAN M study was to investigate if symptoms and/or signs of patients suffering from severe dry eye disease (DED) can be improved by substituting individually optimized artificial tear therapy by high molecular weight hyaluronan (HMWHA) eye drops. In this international, multicenter study, patients with symptoms of at least ocular surface disease index (OSDI) 33 and corneal fluorescein staining (CFS) of at least Oxford grade 3 were included. A total of 84 per-protocol patients were randomized in two study arms. The control group continued to use their individual optimum artificial tears over the study period of eight weeks; in the verum group, the artificial tears were substituted by eye drops containing 0.15% HMWHA. At the week 8 visit, the average OSDI of the verum group had improved by 13.5 as compared to the control group (p = 0.001). The best corrected visual acuity (BCVA) had improved by 0.04 logMAR (p = 0.033). CFS, tear film break-up time (TBUT), Schirmer I, lid wiper epitheliopathy (LWE), mucocutaneous junction (Yamaguchi score), and tear osmolarity were not significantly different between the verum and control groups (p > 0.050). We conclude that for most patients with severe DED, 0.15% HMWHA eye drops provide excellent improvement of symptoms without impairment of dry eye signs

The generalisability of randomised clinical trials : an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer

Purpose None of the key randomised trials on the omission of axillary lymph node dissection (ALND) in sentinel lymph-positive breast cancer have reported external validity, even though results indicate selection bias. Our aim was to assess the external validity of the ongoing randomised SENOMAC trial by comparing characteristics of Swedish SENOMAC trial participants with non-included eligible patients registered in the Swedish National Breast Cancer Register (NKBC). Methods In the ongoing non-inferiority European SENOMAC trial, clinically node-negative cT1-T3 breast cancer patients with up to two sentinel lymph node macrometastases are randomised to undergo completion ALND or not. Both breast-conserving surgery and mastectomy are eligible interventions. Data from NKBC were extracted for the years 2016 and 2017, and patient and tumour characteristics compared with Swedish trial participants from the same years. Results Overall, 306 NKBC cases from non-participating and 847 NKBC cases from participating sites (excluding SENOMAC participants) were compared with 463 SENOMAC trial participants. Patients belonging to the middle age groups (p = 0.015), with smaller tumours (p = 0.013) treated by breast-conserving therapy (50.3 versus 47.1 versus 65.2%, p < 0.001) and less nodal tumour burden (only 1 macrometastasis in 78.8 versus 79.9 versus 87.3%, p = 0.001) were over-represented in the trial population. Time trends indicated, however, that differences may be mitigated over time. Conclusions This interim external validity analysis specifically addresses selection mechanisms during an ongoing trial, potentially increasing generalisability by the time full accrual is reached. Similar validity checks should be an integral part of prospective clinical trials. Trial registration: NCT 02240472, retrospective registration date September 14, 2015 after trial initiation on January 31, 2015Peer reviewe